Skip to main content

Articles

ASH 2018 - Chronic Lymphocytic Leukemia

Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of Patients with CLL with Mutated IGHV

ASH 2018 - Chronic Lymphocytic Leukemia

Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression-Free Survival Compared with Bendamustine plus Rituximab in Untreated Older Patients with CLL

ASH 2018 - Chronic Lymphocytic Leukemia

Results from the Phase 3 iLLUMINATE Study: Ibrutinib + Obinutuzumab as First-Line Treatment in Patients with CLL/SLL

ASH 2018 - Chronic Lymphocytic Leukemia

Acalabrutinib in Treatment-Naïve Chronic Lymphocytic Leukemia: Updated Results from the Phase 1/2 ACE-CL-001 Study

ASH 2018 - Chronic Lymphocytic Leukemia

Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed/Refractory CLL

ASH 2018 - Chronic Lymphocytic Leukemia

MURANO Study: The Impact of Minimal Residual Disease on Long-Term Clinical Outcomes After Venetoclax plus Rituximab

ASH 2018 - Chronic Lymphocytic Leukemia

CLL Treatment Patterns, Dosing, and Sequencing: Interim Analysis Results from the Prospective informCLL Real-World Registry

ASH 2018 - Chronic Lymphocytic Leukemia

The Combination of Ibrutinib with Anti-CD19 CAR T-Cells Shows a High Response Rate in the Treatment of CLL

Original Research, Practice Management

Computed Tomography Colonography Less Costly Than Colonoscopy for Colorectal Cancer Screening of Commercially Insured Patients

Tia Goss Sawhney, DrPH, FSA, MAAA; Bruce S. Pyenson, FSA, MAAA; David Rotter, PhD; Michele Berrios; Judy Yee, MD

Original Research, Practice Management

Alternative Payment Models in Medical Oncology: Assessing Quality-of-Care Outcomes Under Partial Capitation

Derek Ems, MPH; Sharanya Murty, PhD; Bryan Loy, MD; Judith Gallagher, MBA; Laura E. Happe, PharmD, MPH; Teresa L. Rogstad, MPH; Debra Finnel; Jimmy D. Fernandez, MD, MBA

Page 64 of 244
Results 631 - 640 of 2439